Animal models are established, important tools for preclinical safety and efficacy testing. Companies are advancing more “humanized” models to better reflect human responses, while at the same time ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...
The Europe transgenic animal model market is set for robust growth, driven by surging biotechnology investments, demand for ...
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...
The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research BOSTON and SUZHOU, China, June 24, ...
New capability lets sponsors run programs from early rodent proof-of-concept through advanced nonhuman-primate translational studies with a single AAALAC-accredited, USDA-licensed partner. YEMASSEE, S ...
Drug development remains one of the most resource-intensive and failure-prone endeavors in modern science. Despite significant advances in artificial intelligence and computational chemistry, the ...
This article and associated images are based on a poster originally authored by Kieran Casey, Yuzhou Xu, Jichuan Zhang, Shuyue Wang, Yanfei Hu, Ye Tian, Min Lyu, Ziyu Chen, Ya Xu, Qikuan Chen and ...
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results